Compare Eli Lilly And Co (LLY) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Micron Technology, Inc. — how do they compare? Eli Lilly And Co trades at $1,220.55 (market cap $1.08T), while Micron Technology, Inc. trades at $912.39 (market cap $980.90B). The key difference: Eli Lilly And Co and Micron Technology, Inc. are close in size by market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| LLY | MU | |
|---|---|---|
Market Cap | $1.08T | $980.90B |
Sector | Health | Technology |
52-Week High | $1.24K | $1.21K |
52-Week Low | $639.43 | $115.79 |
Enterprise Value | $1.13T | $961.25B |
Dividend Yield | 0.57% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Micron Technology (MU) trades at $921.01, up 6.97% in 24 hours, with strong earnings beats in recent quarters and robust profitability metrics. Technical indicators show a bearish short-term signal, with the stock near resistance at $877. The company exhibits exceptional gross margins of 72.57% and net income margin of 55.91%, supported by surging memory demand and strategic customer agreements.
Outlook remains positive due to AI-driven memory demand and locked-in revenues, but risks include cyclical industry pressures and competitive threats. Analyst consensus is strongly bullish with an average price target of $1,540, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
